Drug Combination Details
| General Information of the Combination (ID: C77475) | |||||
|---|---|---|---|---|---|
| Name | Sesquiterpene lactone + Paclitaxel | + | Cisplatin | ||
| Click to Show/Hide the Each NP or Drug Information of This Combination | |||||
| Name | Sesquiterpene lactone NP Info | Drug Info | |||
| Structure |
|
|
|||
| Name | Paclitaxel NP Info | ||||
| Structure |
|
|
|||
| Disease |
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
| In-vitro Model | SK-OV-3 | CVCL_0532 | Ovarian serous cystadenocarcinoma | Homo sapiens | ||
| OVCAR-3 | CVCL_0465 | Ovarian serous adenocarcinoma | Homo sapiens | |||
| JC cells derived from ovarian cancer patient | Ovarian cancer | Homo sapiens | ||||
| JC-pl cells derived from a pleural effusion after cisplatin treatment | Ovarian cancer | Homo sapiens | ||||
| Experimental
Result(s) |
A synergistic effect of EPD and cisplatin in an ovarian drug resistant cell line as well as a synergistic effect of EPD and paclitaxel in two other ovarian cell lines. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells. J Exp Clin Cancer Res. 2015 Apr 25;34(1):38. | |||
